BRAP (BRCA1-associated protein) antibodies are essential tools in studying the role of BRAP in cellular processes and disease mechanisms. BRAP, also known as BRCA1-associated protein 2 (BRAP2), interacts with BRCA1. a tumor suppressor protein critical for DNA repair, genomic stability, and cell cycle regulation. This interaction links BRAP to pathways involved in maintaining genomic integrity, particularly in response to DNA damage. Dysregulation of BRAP has been implicated in cancer, especially breast and ovarian cancers, where BRCA1 mutations are common. BRAP antibodies enable researchers to detect and quantify BRAP expression in tissues or cell lines, facilitating investigations into its functional roles, protein-protein interactions, and post-translational modifications. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Additionally, BRAP antibodies aid in exploring its potential as a biomarker for cancer prognosis or therapeutic targeting. Recent studies also suggest BRAP involvement in inflammatory and metabolic pathways, expanding its relevance beyond oncology. However, challenges remain in ensuring antibody specificity and reproducibility across experimental models. Continued research using BRAP antibodies may uncover novel mechanisms underlying DNA repair, carcinogenesis, and therapeutic resistance, offering insights for precision medicine strategies.